Pfizer Corporation

Surabhi Srivatsa Srinivasan

Barbra Johnson Sasu

Thomas John Van Blarcom

Tao Sai

Siler Panowski

Roman Galetto

Mathilde Brunnhilde Dusseaux

Niranjana Aditi Nagarajan

Yoon Park

The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).

Chimeric antigen receptors targeting CD70

The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.

Antibodies specific for CD70 and their uses

Growing community of inventors

San Francisco, CA, United States of America

Surabhi Srivatsa Srinivasan